MD Anderson doubles up on cancer 'Moon Shots'

MD Anderson, which has attracted a who's who in immuno-oncology as partners for its Moon Shots R&D program, is adding 6 new cancers to its list of targets. The research institution is doubling down on its moon shots, adding B-cell lymphomas, glioblastoma, HPV, multiple myeloma, colorectal and pancreatic cancers to the list. "As the Moon Shots Program matures, we're transitioning from the foundational phase to the results phase, and some moon shots already are making practice-changing advances in the clinic and in cancer prevention and control," says MD Anderson's Ronald DePinho. Release

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.